ABPI highlights pharma R&D contributions

29 June 2018

UK pharma trade group the Association of the British Pharmaceutical Industry (ABPI) has published data to show how the industry is investing in UK research and development (R&D) despite the future uncertainty of Brexit.

The data published on Disclosure UK – a database of payments and benefits in kind made to UK healthcare professionals (HCPs) and organizations (HCOs) by pharma – shows that the industry spent £371 million ($488 million) on partnerships relating to research and development activities in the UK during 2017. This is a 9.7% increase on 2016.

Spending on R&D activities accounts for three quarters of the total spending disclosed on the database for working in partnership with leading UK health experts and organisations to improve patient care.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK